Introduction {#sec1}
============

Human African trypanosomiasis (HAT), commonly known as "sleeping sickness", is a vector borne-parasitic disease caused by the kinetoplastid *Trypanosoma brucei.* The disease progresses through two stages following an asymptomatic period of several weeks or months. The early stage is usually characterized by malaria-like symptoms, including fatigue, headache, recurrent fever, and swollen lymph nodes. In advanced stages, the disease affects the central nervous system, causing severe neurological and mental disorders and making the individual dependent on others. Infected individuals are weakened, often for many years, causing economic loss, poverty, and social misery. HAT is completely fatal if untreated, and it constitutes a major public health problem in sub-Saharan Africa ([@ref10]). Given the resurgence of both human and animal trypanosomiasis, its epidemic potential, high fatality rate, and significant impact on socioeconomic development, there is a clear need for new therapeutics to control the disease.

The trypanosome life cycle alternates between a mammalian host and the tsetse fly *Glossina* spp., and the different life cycle stages are adapted to survive in each host. In the host-dwelling bloodstream form of the parasite, a protective coat of 5 × 10^6^ glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) homodimers is expressed on the plasma membrane. The parasite survives the immune attack of the host because it undergoes antigenic variation, a process that involves replacement of the VSG coat by another composed of antigenically different VSG molecules ([@ref5]). In addition to VSG, the bloodstream form parasite also expresses less abundant but equally essential glycoproteins, such as the transferrin receptor and the lysosomal p67 glycoprotein ([@ref16]; [@ref1]). This has lead to the investigation of potential therapeutic targets against parasite glycoprotein biosynthesis, such as enzymes of GPI and sugar nucleotide biosynthesis ([@ref40]; [@ref39]).

Sugar nucleotides are the ultimate source of sugar for the majority of glycosylation reactions. They are formed in two main ways: by salvage pathways, involving activation of the sugar using a kinase and subsequent condensation with a nucleotide via a pyrophosphorylase, or by de novo pathways, involving the bioconversion of an existing sugar/sugar nucleotide. In most cases, sugar nucleotides are synthesized in the cytoplasm and used there and/or transported through specific transporters into the lumen of the Golgi apparatus and/or endoplasmic reticulum (ER) where they are used by glycosyltransferases as donor substrates in glycosylation reactions ([@ref12]). In *T.* *brucei*, our knowledge of sugar nucleotide biosynthesis has expanded in the last few years and it has been shown that several steps in the de novo biosynthesis of GDP-fucose ([@ref40]), UDP-galactose (UDP-Gal) ([@ref33; @ref32]; [@ref42]), and UDP-*N*-acetylglucosamine (UDP-GlcNAc) ([@ref37]) occur in the glycosome and are essential for parasite growth. However, several issues remain unsolved, including the pathway to and location of UDP-glucose (UDP-Glc) biosynthesis.

UDP-Glc is the sugar nucleotide acting as a donor of glucose in diverse biochemical pathways and is a central metabolite both in prokaryota and eukaryota. In eukaryotic cells, UDP-Glc is essential in the synthesis of diverse glucose-containing glycolipids, glycoproteins, and a variety of secondary metabolites ([@ref11]). Furthermore, it plays a crucial role for the "quality control" of newly synthesized glycoproteins taking place in the ER ([@ref14]). Thus, UDP-Glc is the glucosyl donor for the unfolded glycoprotein glucosyltransferase (UGGT) involved in the calnexin- and/or calreticulin-mediated glycoprotein quality control refolding cycles in the ER. In *T. brucei*, UGGT has been shown to be essential for parasite growth and survival at 40°C, and a UGGT null mutant was hypersensitive to the effects of the N-glycosylation inhibitor tunicamycin ([@ref15]). UDP-Glc is also the presumed donor for the synthesis of base J (β-[d]{.smallcaps}-glucosylhydroxymethyluracil), a rare deoxynucleotide of unknown function found in telomere-proximal DNA in the bloodstream form of *T.* *brucei* ([@ref43])*.*

The de novo UDP-Glc biosynthetic pathway involves three steps starting from glucose: (a) generation of Glc-6-P, via a hexokinase activity; (b) transfer of the phosphate group from position 6 to position 1, through the action of a phosphoglucomutase; and (c) coupling of Glc-1P to UTP. This last, reversible, step is catalyzed by UDP-Glc pyrophosphorylase (UGP; EC 2.7.7.9).

In this paper, we confirm that the putative *T.* *brucei* UDP-Glc pyrophosphorylase (*TbUGP*) gene (GeneDB ID: Tb10.389.0330) encodes a functional and highly specific UGP enzyme, localize native TbUGP to the glycosomes and describe its high-resolution crystal structure in complex with UDP-Glc.

Results {#sec2}
=======

Identification and expression of TbUGP {#sec3}
--------------------------------------

A BLASTp search of the *T.* *brucei*-predicted protein database with *Homo sapiens*, *Saccharomyces cerevisiae*, and *Leishmania major* UDP-Glc pyrophosphorylase (UGP) amino acid sequences (NCBI accession nos. NP_001001521, NP_011851, and XP_001682505.1, respectively) revealed a single putative *TbUGP* gene (GeneDB ID: Tb10.389.0330). This single putative *TbUGP* locus was also confirmed by Southern blotting of restriction endonuclease digested genomic DNA (data not shown). The predicted amino acid sequence of Tb10.389.0330 contains the highly conserved nucleotide binding (NB) loop (KLNGGLGTXMGX~4~K) and 16 of the 17 residues shown to be involved in substrate binding (SB) in the UGP crystal structures from other organisms ([Figure 1](#fig1){ref-type="fig"}) ([@ref19]). The only residue involved in catalytic activity that is different in the *T.* *brucei* sequence is Gly221, which is an Ile in the *H.* *sapiens* and *Bos* *taurus* orthologues. TbUGP was found to have 37% amino acid identity with the human enzyme.

![Alignment of UDP-Glc pyrophosphorylase predicted amino acid sequences. The sequences of *T.* *brucei*, *T.* *cruzi*, *L.* *major*, *Rattus norvegicus*, *H.* *sapiens* and *Candida albicans* were aligned using Clustal W (http://www.ebi.ac.uk/) and Jalview (http://www.jalview.org/). Residues participating in contacts with the nucleoside (black circles), phosphate (triangles), and glucose residue (square) are highlighted. The highly conserved nucleotide-binding (pyrophosphorylase motif) loop (dashed line) and substrate-binding loop (full line) are boxed](cwq115fig1){#fig1}

The *TbUGP* open reading frame was amplified from *T.* *brucei* strain 427 genomic DNA by polymerase chain reaction (PCR) using a high-fidelity polymerase, and the consensus sequence (EMBL nucleotide sequence database accession no. FN662556) predicts a 485-amino acid protein of 54,507 Da. The same sequence was also obtained when the gene was amplified from cDNA (EMBL nucleotide sequence database accession no. FN662557) using the same *TbUGP* 3′-primer and a 5′-spliced leader primer described in [*Materials and* *methods*](#sec11){ref-type="sec"}. *T.* *brucei* genes are generally free of introns and are transcribed in polycistronic units that are processed by trans-splicing with a common 35-nucleotide "miniexon" or "spliced leader" sequence ([@ref20]). Comparison of the cDNA and genomic sequences allowed us to determine the precise site of trans-splicing for this gene, which, as expected, occurs in a polypyrimidine tract, 113 bases upstream of the ATG codon. The predicted amino acid sequence for TbUGP from *T.* *brucei* strain 427 was almost identical to that in the *T.* *brucei* strain 927 genome database, except for substitution of Ser for Phe at position 54 and Ser for Asn at position 473. Neither residue is believed to be involved in the active site.

Semi quantitative RT (reverse transcription)--PCR, using RNA from *T.* *brucei* bloodstream and procyclic form, showed that the TbUGP mRNA is present in both life cycle stages ([Figure 2](#fig2){ref-type="fig"}A).

![Detection of *TbUGP* mRNA and TbUGP protein in *T.* *brucei*. (**A**) RT--PCR reaction using 8, 16, 32 and 40 ng of RNA from *T.* *brucei* bloodstream (BSF) or procyclic (PCF) form parasites. (**B**) TbUGP western blot. Lane 1, *E.* *coli* recombinant TbUGP (25 ng); lane 2, BSF total lysate (5 × 10^6^ cell equivalent) and lane 3, TbUGP immunoprecipitate (2 × 10^8^ cell equivalent). The top arrow on the right indicates the native TbUGP, which has a slightly lower molecular weight than the recombinant protein due to the His~6~ tag, and the faint band underneath is the heavy chain of IgG used in the immunoprecipitation. The molecular weight standards (kDa) are shown on the left](cwq115fig2){#fig2}

Polyclonal antibodies against the recombinant enzyme (see [*Materials and* *methods*](#sec11){ref-type="sec"}) were raised in mice and affinity purified against immobilized recombinant protein. These antibodies failed to detect any relevant cross-reactivity with other proteins present in the cell ([Figure 2](#fig2){ref-type="fig"}B, lane 2) and due to the low abundance of TbUGP in the cell, it could only be detected in immunoprecipitates of 2 × 10^8^ bloodstream form cells ([Figure 2](#fig2){ref-type="fig"}B, lane 3). These results show the monospecificity of the antibodies used in the cellular localization experiment ([Figure 5](#fig5){ref-type="fig"}) and also suggest that TbUGP protein expression level is similar to other enzymes involved in sugar nucleotide biosynthesis ([@ref33]).

![Subcellular localization of TbUGP. Wild-type bloodstream form *T.* *brucei* cells were stained with affinity-purified mouse anti-TbUGP and Alexa 488-conjugated anti-mouse antibody (green channel, panels A, E) and with rabbit anti-GAPDH and Alexa 594-conjugated anti-rabbit antibody (red channel, B) to mark the glycosomes, or rabbit anti-enolase and Alexa 594-conjugated anti-rabbit antibody (red channel, F) to mark the cytosol. Merged images are shown in panels (C, G) and corresponding phase contrast images are shown in panels (D, H)](cwq115fig5){#fig5}

Expression of monomeric TbUGP in *Escherichia* *coli* {#sec4}
-----------------------------------------------------

The *TbUGP* ORF was cloned into a modified pET15b vector so that it contains a PreScission™ protease site between the protein and the His~6~ tag. This plasmid was expressed in *E.* *coli* and the protein purified as described in [*Materials and* *methods*](#sec11){ref-type="sec"} ([Figure 3](#fig3){ref-type="fig"}A). After purification by nickel affinity chromatography, the recombinant TbUGP eluted as a single peak by gel filtration with a retention time consistent with a monomeric 55 kDa protein. Protein with the His~6~ tag removed by PreScission™ protease also eluted as a monomer by gel filtration, indicating that the N-terminal His~6~ tag does not influence quaternary organization. Since oligomerization has a key role in the regulation of activity for other UGPs ([@ref22]), UDP-Glc synthetic activity was assayed in each fraction from gel filtration and this demonstrated that the monomeric state is active. Furthermore, analysis of the pooled active fractions of recombinant His~6~-TbUGP protein by analytical ultracentrifugation (at 0.75 mL mg/mL) indicated that the majority of TbUGP is monomeric at this concentration ([Figure 3](#fig3){ref-type="fig"}B), although some dimer and possibly higher oligomers were detected. The ultracentrifugation data were unaffected by the presence or absence of UTP and Glc-1-P (data not shown). This result is in agreement with the data previously published for *L.* *major* and barley UGP, which were also found to be active as monomers ([@ref22]; [@ref19]; [@ref35]) but is in contrast with human UGP which is octameric ([@ref2]).

![Purification and characterization of recombinant His~6~-TbUGP. (**A**) Coomassie blue-stained SDS--PAGE gel of proteins in uninduced *E.* *coli* cells (lane 1) and in IPTG-induced *E.* *coli* cells (lanes 2--7); total protein (lane 2), pellet after lysis and centrifugation (lane 3), supernatant after lysis and centrifugation (lane 4), flow through after Ni-affinity chromatography (lane 5), His~6~-TbUGP purified by Ni-affinity chromatography and elution with imidazole (lane 6). Lane 7, His~6~-TbUGP further purified by gel filtration. (**B**) Analytical ultracentrifugation profile of recombinant TbUGP at a final concentration of 0.75 mg/mL](cwq115fig3){#fig3}

TbUGP enzyme kinetics and specificity {#sec5}
-------------------------------------

We measured the TbUGP forward reaction (i.e., the production of UDP-Glc and pyrophosphate \[PPi\] from Glc-1-P and UTP) using recombinant His~6~-TbUGP. The reactions were started by adding the enzyme and stopped by boiling. After adding an excess of 2 mM NaOH, aliquots of the resulting solutions were analyzed by anion exchange high-performance liquid chromatography (HPLC), as described in [*Materials and* *methods*](#sec11){ref-type="sec"}, allowing the resolution and detection by ultraviolet (UV) absorbance of UDP-Glc and UTP. Using this method, we determined the optimal pH for the TbUGP forward reaction to be between pH 6.0 and 7.5 ([Figure 4](#fig4){ref-type="fig"}A) and showed that TbUGP was, as expected, divalent cation-dependent (with an optimal assay condition of 10 mM Mg^2 +^). The enzyme could also be activated by Mn^2 +^ and Co^2 +^, but not by Zn^2 +^ or Cu^2 +^ (data not shown).

![pH optimum and substrate specificity of recombinant TbUGP. (**A**) The pH optimum of TbUGP was determined by comparing the yields of UDP-Glc using the HPLC assay. The error bars indicate the SD values (*n* = 3). UDP-Glc was quantified by comparison with a UDP-Glc calibration curve. (**B**) The specificity of TbUGP was analyzed using the HPLC assay and different sugar-1-phosphate substrates, as indicated. Only Glc-1-P produced a UV-absorbing peak in the sugar nucleotide region of the chromatogram](cwq115fig4){#fig4}

The substrate specificity of TbUGP was also defined with the HPLC assay using a variety of sugar-1-phosphate substrates ([Figure 4](#fig4){ref-type="fig"}B). Using Glc-1-P as a substrate, a single peak was observed with a retention time of 25.5 min, coeluting with an authentic UDP-Glc standard. No sugar nucleotide peaks were observed in the absence of TbUGP or when GalNAc-1-P, GlcNAc-1-P or Gal-1-P was used as a substrate. These data showed that Glc-1-P was the preferred substrate of TbUGP under these conditions.

The purified recombinant TbUGP protein was then kinetically characterized for the forward reaction using a discontinuous colorimetric coupled assay ([@ref37]). In this case, the PPi product is converted to inorganic phosphate (Pi) by pyrophosphatase, and the Pi is subsequently reacted with malachite green. Using this assay, the specific activity and apparent *K*~m~ values for UTP and Glc-1-P were determined. The linearities of the Lineweaver--Burke plots showed that the *T.* *brucei* enzyme obeyed simple Michaelis--Menten kinetics for both substrates. The specific activity of the recombinant TbUGP was 5.2 × 10^4^ μmol PPi released/min mg protein, and the apparent *K*~m~ values for UTP and Glc-1-P were 53 ± 8 μM and 122 ± 17 μM, respectively (data not shown). These values of are well within the normal ranges reported for UGPs from other eukaryotic organisms, including *L. major* UGP ([@ref19]).

Subcellular localization of TbUGP in bloodstream form *T.* *brucei* {#sec6}
-------------------------------------------------------------------

Localization studies were conducted using affinity-purified polyclonal mouse anti-TbUGP antibody together with either rabbit anti-GAPDH antibody (as a glycosomal marker) or rabbit anti-enolase (as a cytosolic marker). The secondary antibodies were anti-mouse Alexa 488 (green) and anti-rabbit Alexa 594 (red). The data show substantial co-localization of the anti-TbUGP with anti-GAPDH signals ([Figure 5](#fig5){ref-type="fig"}A, B, C) and an absence of co-localization of the anti-TbUGP with anti-enolase signals ([Figure 5](#fig5){ref-type="fig"}E, F, G). These data indicate that TbUGP localizes to the glycosome microbodies of bloodstream form *T.* *brucei*. Interestingly, although all of the GAPDH-staining glycosomes appear to also contain TbUGP (compare [Figure 5](#fig5){ref-type="fig"}A and B), the ratio of TbUGP to GAPDH staining may be variable. Although the majority of TbUGP staining is glycosomal, we cannot rule out that some TbUGP may be also present in the cytosol.

Crystal structure of recombinant TbUGP {#sec7}
--------------------------------------

The high-resolution crystal structure of a TbUGP construct lacking only the N-terminal Met-Pro sequence and complexed with UDP-Glc was solved (PDB accession no. 3GUE) by molecular replacement using the *L.* *major* UGP/UDP-Glc complex closed conformation structure ([@ref35]). The crystallographic statistics related to the structure determination of TbUGP and its complex with UDP-Glc are listed in [Table I](#tab1){ref-type="table"}. The asymmetric unit contains two protein chains, labeled A and B. The crystal contacts between A and B are not substantial. Several crystal contact interfaces are mediated by moieties from the crystallization buffer (i.e., glycerol, PEG, and sulfate), and thus protein subunit oligomerization is not implied by the crystallographic data ([Figure 6](#fig6){ref-type="fig"}A). Several surface loops and residues were not modeled due to insufficient electron density. These include the first eight N-terminal residues in both chains and residues between Asp264 and Gln272 in monomer A. In the case of monomer B, the areas not modeled are (corresponding to PDB numbering) B61--B70, B123--124, B266--B271, and the carboxy-terminal residue B483. Because monomer A is more complete, we use herein this model for our analysis. Although the resolution is fairly high, no peaks corresponding to magnesium could be found in the electron density. Table ICrystallographic data of TbUGP (PDB accession no. 3GUE)**Data collection**Space groupC2Cell dimensionsa (Å)167.7b (Å)77.49c (Å)112.21alpha90.00beta117.88gamma90.00Wavelength1.5418Resolution25--1.92 (1.99--1.92)Measured reflections1,716,578Unique reflections96,124Rsym0.120 (0.706)I/sigI10.38 (1.33)Completeness (%)98.7 (90.6)Redundancy3.1 (3.0)**PDB code**3GUE**Refinement**Resolution25.0--1.92Number of reflections91,276Test set4791Rwork/Rfree0.243/0.294Number of atoms8155Mean Bfactor27.931Ramachandran favored (%)97.81Ramachandran disallowed (%)0Root mean square deviationsBond lengths (Å)0.016Bond angles (°)1.519 Fig. 6Crystal structure of TbUGP in complex with UDP-Glc. (**A**) Representation of the dimer observed as an artifact of crystallization. (**B**) Illustration of the three classical UGP domains present in TbUGP: the N-terminal domain (green), the catalytic central domain (red), and the C-terminal domain (yellow). (**C**) Overall structure comparison of TbUGP (green) with the unbound (yellow) and bound (cyan) forms of LmUGP. Arrow 1 shows the additional 12 degree closure of TbUGP onto substrate compared to both open and closed conformations of LmUGP. The actual active site is aligned almost perfectly with the closed LmUGP structure. Arrow 2 shows the substrate-binding loop (SB loop) aligning well with the closed conformation. Arrow 3 shows the nucleotide-binding loop (NB loop), similar to the one in LmUGP. (**D**) Electrostatic potential of TbUGP showing the extensive basic patch covering the substrate-binding pocket. Images were generated by Pymol

The TbUGP structure is similar to those of other previously described eukaryotic UGP structures ([@ref31]; [@ref23]; [@ref35]). It contains an N-terminal domain (amino acids Pro2--Thr45, Asn164--Val188, Pro328--Ala352, green) and a C-terminal domain (Asp388--Glu485, yellow) flanking the central catalytic domain (red, [Figure 6](#fig6){ref-type="fig"}B). The central catalytic domain forms a Rossman fold consisting of an eight-stranded mixed beta-sheet, flanked by an outer layer of helices that then branches off into the C-terminal left-handed beta helix (residues 408--485), containing a strongly hydrophobic core. Density is missing in the TbUGP data for residues Asp264--Gln272, which are highly solvent exposed due to crystal packing. This missing area corresponds to a flexible, protruding loop (Arg261--Leu280) also found in the *L.* *major* structure ([Figure 6](#fig6){ref-type="fig"}C).

The structure was solved using the "closed" conformation of LmUGP, and we see that TbUGP is also in the closed conformation and appears to be even more firmly closed onto the substrate. Structure-based comparison with LmUGP (PDB accession no. 2OEG) reveals that TbUGP C-terminal domain (R331--L349) moves an additional 12 degrees towards the catalytic domain pocket compared to the LmUGP in closed configuration ([Figure 6](#fig6){ref-type="fig"}C). The active site is located in the central catalytic domain, in a pocket with distinctive positive electrostatic potential ([Figure 6](#fig6){ref-type="fig"}D).

The SB loop (Thr251--Gly258) aligns well with LmUGP which is expected since both structures were obtained in the presence of UDP-Glc. The NB loop also moves closer to the substrate pocket, however, less dramatically compared to the 12 degree motion of the C-terminus lobe. The LBH as well is compressed in towards the pocket. The overall effect of all these motions is to occlude the SB pocket, which can be seen in [Figure 6](#fig6){ref-type="fig"}C and D.

Active site of the UDP-Glc complex {#sec8}
----------------------------------

The structure of TbUGP in complex with the product of the forward reaction, UDP-Glc, confirms the location of the active site of the enzyme ([Figure 6](#fig6){ref-type="fig"}B, C, D). TbUGP contains all of the crucial amino acids that were earlier implicated in catalysis or SB of UGPs from other eukaryotic species ([@ref2]; [@ref8]; [@ref23]). For instance, Lys367 of *Solanum tuberosum* UGP, located in the C-terminal domain and crucial for catalysis, corresponds to Lys377 in the *T.* *brucei* enzyme.

The UDP-Glc is bound in a deep cleft located at the center of the catalytic domain that consists of highly conserved residues. The SB loop (Thr251--Gly258) and the NB loop (Lys82--Lys97), both located in the central catalytic domain, are well conserved ([Figure 1](#fig1){ref-type="fig"}).

The uridine ring stays parallel to Gly85, Gly86, and Gly191, which probably fixes the ring by hydrophobic interactions. Gln163 side chain oxygen and nitrogen also contribute by interaction with the heteroatoms in the ring.

In the case of the ribose ring, O-2 seems to be interacting with the backbone nitrogen of Gly86 residue, and O-3 is interacting with the backbone nitrogen of Gly221. The rest of the interactions are involving water molecules so, as proposed for the *L.* *major* structure, analogues of UDP-Glc modified in the ribose residue could be inhibitory ([@ref35]).

The phosphates are fixed by a mixture of hydrogen bonds, with Lys377 stabilizing both the α-phosphate and the oxygen in the phosphate diester link. The α-phosphate also interacts closely with a water molecule and a glycerol that appears inside the active site (which is probably replaced by water in solution). The β-phosphate interactions include several water molecules, Lys 256 and His192.

The glucose residue is fixed via several hydrogen bonds, as observed in other UGPs. In this case, the OH-4 of glucose is involved in three different possible interactions, with Gly258 (with both the CO and N from the amide bond) and with Asn303; the OH-2 interacts with Glu281 and His192.

Accession numbers {#sec9}
-----------------

Nucleotide sequences have been deposited in the EMBL nucleotide sequence database. Accession no. FN662556 corresponds to TbUGP *ORF.* Accession no. FN662557 corresponds to the sequence obtained by gene amplification from cDNA, as described in [*Materials and* *methods*](#sec11){ref-type="sec"}.

Coordinate and structure factors for TbUGP in complex with UDP-Glc have been deposited in the RCSB Protein Data Bank (www.pdb.org) with accession number 3GUE.

Discussion {#sec10}
==========

UGPs have been purified and characterized from a wide range of prokaryotic and eukaryotic organisms, including *Mycobacterium tuberculosis* ([@ref18]), *Arabidopsis thaliana* ([@ref23]), and *B.* *taurus* ([@ref36]). The eukaryotic enzymes have no significant sequence similarity to their prokaryotic counterparts and, whereas other enzymes of sugar nucleotide metabolism in *T.* *brucei*, like UDP-Glc 4′-epimerase, appear to have a bacterial origin ([@ref33]), TbUGP clearly belongs of the eukaryotic family of UGPs and no putative bacterial UGP homologues could be found in the *T.* *brucei* genome. The kinetoplastid UGPs belong to their own phylogenic clade ([@ref19]).

There is nothing particularly remarkable about the enzymatic properties of TbUGP, apart for its strict specificity for Glc-1-P which differentiates it from the UGPs of the parasite's human and bovine hosts that can also utilize Gal-1-P for the synthesis of UDP-Gal ([@ref41]). The molecular geometries observed in the TbUGP crystal structure around the OH-2 and OH-4 of the glucose residue of bound UDP-Glc are probably responsible for its strict substrate specificity. Thus, the tight network of interactions with the OH-4 of the glucose residue explains why UDP-Gal (an epimer of UDP-Glc at the OH-4 position) is not a substrate, and the interactions of the OH-2 of the glucose residue with residues Glu281 and His192 provide the steric constraints that prevent the binding of 2-deoxy-2-*N*-acetamido sugars (as in UDP-GlcNAc and UDP-GalNAc). The strict sugar-specific substrate specificity of TbUGP is reminiscent of other *T.* *brucei* sugar nucleotide biosynthetic enzymes, for example, TbGalE (UDP-Glc 4′-epimerase) and TbUAP (UDP-GlcNAc pyrophosphorylase) interconvert and utilize exclusively UDP-Glc/UDP-Gal ([@ref32]) and GlcNAc-1-P ([@ref37]), respectively, whereas their mammalian counterparts can also interconvert and utilize UDP-GlcNAc/UDP-GalNAc and GalNAc-1-P, respectively.

Another difference between the parasite and human UGPs relates to quaternary structure: TbUGP, like *L.* *major* UGP, is predominantly monomeric and fully active in its monomeric state whereas the human enzyme, like that of other mammals and of fungi, is active as an octamer ([@ref41]; [@ref2]; [@ref31]). Interestingly, both AGX1, the extensively characterized dimeric human UDP-GlcNAc pyrophosphorylase ([@ref25]), and *Arabidopsis* UGP ([@ref23]) have a C-terminal domain loop responsible for dimerization, and in *S.* *cerevisiae* UGP, this feature has been shown to be essential for stabilization of the octameric active form. The absence of a comparable C-terminal domain loop in TbUGP may explain its natural monomeric state.

Sequestration by oligomerization has been suggested to be important in the regulation of UGPs, particularly in plants ([@ref3]). Other possible methods of regulation include *O*-GlcNAc-ylation, as found for human UGP ([@ref44]), differences in N-terminal acetylation status, as demonstrated for UGPase isoforms in rice ([@ref3]), and phosphorylation, as shown by the down-regulation of yeast UGP by phosphorylation by a serine/threonine kinase ([@ref31]). Since cytosolic *O*-GlcNAc-ylation does not occur in *T.* *brucei*, this may be ruled out as a regulatory mechanism for TbUGP. Furthermore, a recent analysis of the bloodstream form *T.* *brucei* phosphoproteome ([@ref26]) did not identify TbUGP as a phosphoprotein (although its low abundance and glycosomal location might have prevented its detection). It may be that TbUGP and metabolic flux into the UDP-hexose pathways, like the non-allosteric regulation of glycolysis ([@ref13]), is principally regulated by glycosomal compartmentation in *T.* *brucei*.

Glycosomes of trypanosomatids belong to the microbody family of organelles, containing the glyoxysomes of plants and peroxisomes of all other eukaryotes. The organelles resemble each other with respect to morphology and metabolic functions, but a unique feature of trypanosomatid glycosomes is their essential role in carbohydrate metabolism, i.e., glycolysis, gluconeogenesis, glycerol metabolism, the pentose-phosphate pathway ([@ref24]), and much of sugar nucleotide biosynthesis ([@ref33]; [@ref40]; [@ref37]), including TbUGP (this paper). Glycosomal proteins are targeted to these organelles via a peroxisomal targeting sequence (PTS), which can be located in the C-terminus (PTS-1) or N-terminus (PTS-2) of the protein. Internal PTS sequences have also been proposed as another targeting mechanism, with *T. cruzi* phosphoglucomutase as an example ([@ref29]). TbUGP does not contain traditional trypanosome PTS sequences ([@ref27]). However, several internal PTS-1-like sequences can be found, such as -NRV- (N164--V166), -GKL- (G203--L205), -SNG- (S219--G221), or -SDL- (S380--L382). Of these four sequences, SNG is in the active site, and only GKL seems to be exposed to the solvent in the crystal structure. Nevertheless, considering that the apo-structure will be different to the protein in complex with UDP-Glc ([@ref35]), none of these sequences can be discounted until appropriate mutagenesis experiments are performed. In cases where no targeting sequence exists, it has been proposed that proteins can traffic to the glycosome by "piggybacking" on other PTS-targeted proteins ([@ref30]; [@ref38]). One such candidate for TbUGP is UDP-Glc 4′-epimerase, TbGalE, which has a TKL C-terminal PTS-1 sequence and which works in partnership with TbUGP in the biosynthesis of UDP-Gal ([@ref33]). In any case, it would now appear that all enzymes involved in the UDP-hexose biosynthetic pathway exist in the glycosome, since hexokinase (Glc → Glc-6-P), TbUGP (Glc-1-P → UDP-Glc), and TbGalE (UDP-Glc ↔ UDP-Gal) have all been experimentally localized there. The only missing link is the identity and location of the *T.* *brucei* phosphoglucose mutase (Glc-6-P → Glc-1-P) activity, for which there is no obvious candidate gene in *T.* *brucei*, although the *T.* *cruzi* enzyme has been identified and localized to glycosomes ([@ref29]). The fact that UDP-Gal, UDP-Glc, and UDP-GlcNAc are all synthesized in the glycosome and used in the ER and/or nucleus reinforces the hypothesis that glycosomal sugar nucleotide transporters and/or antiporters may exist ([@ref37]).

The related parasite *L.* *major* has a salvage pathway whereby it can take up galactose and convert it, via galactokinase and Isselbacher pathway UDP-sugar pyrophosphorylase, to UDP-Gal ([@ref6]). In contrast, this salvage pathway is completely absent in *T.* *brucei*, and the organism is entirely dependent on the de novo synthesis of UDP-Gal for glycoprotein biosynthesis ([@ref33]; [@ref42]). We may therefore assume that TbUGP, which provides UDP-Glc for epimerization to UDP-Gal, is also essential and a potential drug target for human African sleeping sickness. Indeed, TbUGP may be a superior target to the TbGalE epimerase because UDP-Glc is also required as the glucosyl donor for the UGGT and for the synthesis of base J (β-[d]{.smallcaps}-glucosylhydroxymethyluracil) ([@ref43]; [@ref15]). The crystal structure of TbUGP described here will help in the design of TbUGP inhibitors and in assessing their modes of binding. The therapeutic potential of TbUGP as a drug target will obviously depend on our ability to find drug-like parasite-specific TbUGP inhibitors.

Materials and methods {#sec11}
=====================

DNA isolation and manipulation {#sec12}
------------------------------

Plasmid DNA was purified from *E.* *coli* (DH5α) using the Qiagen Miniprep or Maxiprep kit as appropriate. Gel extraction was performed using QIAquick kits. Custom oligonucleotides were obtained from the University of Dundee oligonucleotide facility. *T. brucei* genomic DNA was isolated from 1 × 10^8^ bloodstream form cells using DNAzol (Helena Biosciences, Gateshead, UK). All *T.* *brucei* cell cultures are mycoplasma free.

Cloning and sequencing of TbUGP {#sec13}
-------------------------------

The *TbUGP* open reading frame identified in the *T.* *brucei* genome database (Tb10.389.0330) was amplified by PCR from genomic DNA with Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) using a forward primer containing an *NdeI* site (underlined), 5′-ggaattc[catatg]{.ul}ccgctaaaccctcc-3′, and a reverse primer containing a *XhoI* site (underlined), 5′-cgc[ctcgag]{.ul}ctactcgactaccacaacct-3′. The products of three separate PCR reactions were cloned into a modified pET15B (Invitrogen) vector with a PreScission™ protease site replacing the thrombin cleavage site (a kind gift of Jon Urch and Daan van Aalten, College of Life Sciences, University of Dundee), and a representative clone from each PCR was sequenced in both directions. All three clones were identical.

The TbUGP sequence was also obtained when the gene was amplified from cDNA using the same *TbUGP* 3′-primer and a 5′-spliced leader primer 5′-gcccgctattattagaacagtttctgta-3′.

All plasmids were verified by sequencing (DNA Sequencing Service, College of Life Sciences, University of Dundee; www.dnaseq.co.uk).

RT--PCR {#sec14}
-------

Total RNA from bloodstream form (BSF) and procyclic form (PCF) *T. brucei* was extracted using the RNAeasy extraction kits with on-column DNAse digestion (RNAse-free DNAse; Qiagen, Valencia, CA). RNA samples were treated with Omniscript reverse transcriptase (Qiagen) to generate cDNA. The cDNAs were then amplified by PCR using Taq polymerase and *TbUGP* ORF primers (described in *Cloning and sequencing of TbUGP*) and Dol-P-Man synthetase primers (forward 5′-aatggatgcggaccttcagcacccac-3′, reverse 5′-tagaaccgtgagcgcggtgccatac-3′) as a constitutively expressed positive control.

Protein expression and purification {#sec15}
-----------------------------------

The aforementioned modified pET15B plasmid containing the *TbUGP* ORF was used to transform *E. coli* BL21 (DE3) cells. Selected clones were grown aerobically at 37°C in Lysogeny broth (LB) medium containing ampicillin (100 μg/mL) to a culture density of OD 0.6. The expression of His~6~-TbUGP was induced by adding isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. Cells were grown overnight at 16°C and harvested by centrifugation. The *E.* *coli* cells were resuspended in 50 mM Tris--HCl (pH 7.7), 0.15 M NaCl (buffer A), containing 50 mM imidazole, 1 mg/mL lysozyme, and Complete Protease Inhibitor Cocktail Tablets (Roche Diagnosis, GmbH, Mannheim, Germany). After lysis in a French press, the lysate was cleared by centrifugation (20,000 × *g*, 30 min, 4°C) and the supernatant passed through a 0.45-μm filter. Purification of His~6~-TbUGP was performed using a 5-mL His-Trap column (GE Healthcare, Uppsala, Sweden) previously equilibrated with 30 mL of buffer A containing 50 mM imidazole. After sample loading, the column was washed and His~6~-TbUGP eluted by application of a 50--350-mM imidazole gradient (AKTA purifier, GE Healthcare, Uppsala, Sweden). The fractions obtained were checked by sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS--PAGE), and those containing His~6~-TbUGP were pooled and concentrated using a Vivaspin concentrator (Sartorius Stedi, UK Ltd., Epson, UK 10 kDa molecular weight cut off) at 4°C. As a second step, recombinant His~6~-TbUGP was loaded onto a Superdex 200 HR30 HPLC column (GE Healthcare, Uppsala, Sweden). Proteins were eluted at 0.5 mL/min in buffer A and monitored by absorbance at 280 nm. Fractions (2 mL) were collected and the presence of His~6~-TbUGP in peak fractions verified by SDS--PAGE. The final yield was 10 mg/L culture. After gel filtration, His~6~-TbUGP can be stored at − 80% in buffer A, 10% glycerol for several months. To cleave the His~6~ tag, the fusion protein was digested with GST-PreScission protease (a kind gift of Daan Van Aalten, University of Dundee) in 50 mM Tris pH 7.7, 0.150 mM NaCl, and 1 mM dithiothreitol (DTT) for 16 h at 4°C. Recombinant proteins were identified in the Proteomics and Mass Spectrometry Facility, College of Life Sciences, University of Dundee.

For crystallization, TbUGP was cloned into a modified pET15b vector containing a TEV protease site and transformed into *E. coli* BL21(DE3)-V2R-pRARE2 cells. Selected cells were inoculated into 10 mL of LB with ampicillin/chloramphenicol (50 μg/mL and 25 μg/mL, respectively) and incubated with shaking at 250 rpm overnight at 37°C. The culture was transferred into 50 mL of TB with 50 μg/mL ampicillin in a 250-mL shaking flask and incubated at 37°C for 3 h. Then the culture was transferred into 1.8 L of TB with 50 μg/mL kanamycin and 0.3 mL of antifoam (Sigma, Dorset, UK) and cultured using the LEX system (Harbinger Biotechnology and Engineering, Ontario Canada) to an OD~600~ of \~ 5, induced with 0.5 mM IPTG overnight at 15°C and harvested by centrifugation. Pellets were resuspended in binding buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid \[HEPES\] pH 7.5, 500 mM NaCl, 5 mM imidazole, and 5% glycerol) with the addition of protease inhibitors (1 mM benzamidine and 1 mM phenylmethyl sulfonyl fluoride). Prior to mechanical lysis, each pellet from 1 L of culture was pretreated with 0.5% 3-(\[3-cholamidopropyl\]-dimethylammonio)-1-propanesulfonate and 500 units of benzonase for 30 min at room temperature. Cells were mechanically lysed with a microfluidizer (Microfluidizer Processor, M-110EH), and the cell lysate was centrifuged using a Beckman JA-25.50 rotor at \~ 75,000 × *g* (24,000 rpm) for 20 min at 10°C. The cleared lysate was loaded onto a column pre-packed with 10 g DE52 (Whatman) anion exchange resin (previously activated with 2.5 M NaCl and equilibrated with binding buffer), and subsequently onto a 3-mL Ni-NTA (Qiagen) column pre-equilibrated with binding buffer. After the lysate was loaded, the DE52 was further washed with 20 mL of binding buffer. The Ni-NTA column was then washed with 200 mL of wash buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 30 mM imidazole, and 5% glycerol) at 2--2.5 mL/min. After washing, the protein was eluted with 15 mL of an elution buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 250 mM imidazole, and 5% glycerol). To remove the His~6~ tag, the protein was treated with TEV protease and dialysed in 10 mM HEPES, 500 mM NaCl, 5 mM imidazole, and 5 mM DTT overnight. The sample was passed through the Ni-NTA column one more time before being loaded onto a Sephadex S200 26/60 gel filtration column (GE Healthcare) pre-equilibrated with 10 mM HEPES, pH 7.5 and 500 mM NaCl, 5 mM DTT. The collected fractions corresponding to the correct eluted protein peak were concentrated using a 15-mL Amicon Ultra centrifugal filter device (Millipore, Billerica, MA).

Analytical ultracentrifugation {#sec16}
------------------------------

Recombinant TbUGP (0.75 mg/mL in buffer A) was analyzed by sedimentation velocity using a Beckman Optima XL-1 Analytical Ultracentrifuge with an AN50-Ti rotor at 32,000 rpm at 20°C. Absorbance data (72 scans at 280 nm) were collected and analyzed using the SEDFIT program ([@ref34]). TbUGP was assumed to be globular, and its density was predicted from its amino acid composition.

UDP-Glc pyrophosphorylase activity assays {#sec17}
-----------------------------------------

Two methods were used to assay TbUGP, an HPLC assay and a discontinuous coupled colorimetric assay, as previously described for *T.* *brucei* UDP-GlcNAc pyrophosphorylase ([@ref37]).

Briefly, the HPLC assay used 0.05 μg His~6~-TbUGP incubated in 100 μL of the HPLC assay buffer (50 mM Tris--HCl pH 7.2, 250 μM UTP, 10 mM MgCl~2~, 1 mM DTT, 250 μM Glc-1-P) for 8 min, terminated by boiling for 5 min. The samples were diluted in 2 mM NaOH and analyzed using a Dionex high-pH anion exchange chromatography HPLC system. To determine substrate specificity, Glc-1-P was substituted by Gal-1-P, GlcNAc-1-P, or GalNAc-1-P (all at 250 μM). For metal ion dependence, MgCl~2~ was replaced with CuCl~2~, ZnCl~2~, CoCl~2~, or MnCl~2~. For pH dependence, the Tris--HCl buffer was replaced with a 50-mM sodium acetate for pH 4.0--6.0 and 50-mM *N*-cyclohexyl-3-aminopropanesulfonic acid buffer for pH higher than 9.0.

The TbUGP colorimetric assay was performed with 0.0125 μg of His~6~-TbUGP in a 96-well plate format (Nunc™) in 12.5 mM Tris--HCl pH 7.2, NaCl 150 mM, 500 μM UTP, 500 μM Glc-1-P, 10 mM MgCl~2~, 1 mM DTT, bovine serum albumin (BSA) 0.1 mg/mL, and 1 U/mL pyrophosphatase (Sigma) to a final volume of 50 μL. The reaction was left for 8 min at room temperature and terminated by the addition of 100 μL of the color reagent (0.2% ammonium molybdate, 0.5% Triton X-100, 0.7 N HCl, 0.03% malachite green). Absorbance at 620 nm was measured after 20 min using a SpectraMax 340 PC (Molecular Devices, Sunnyvale, CA).

TbUGP localization {#sec18}
------------------

Two Balb/c adult mice were used to raise polyclonal antibodies against His~6~-tagged TbUGP protein (about 0.1 mg per mouse) with Freund's complete adjuvant. Each mouse received two further immunizations with Freund's incomplete adjuvant over 2 months. Antibodies were then affinity purified on CNBr-Sepharose-immobilized TbUGP that had had its His~6~ tag removed with PreScission™ protease. Similar protocol was used to immunize two New Zealand rabbits with 0.5 mg of purified TbUGP protein per animal.

Wild-type bloodstream form *T.* *brucei* cells were grown in HMI-9 medium to a density of 1 × 10^6^ cells/mL, harvested by centrifugation and resuspended in trypanosome dilution buffer (0.1 M Na~2~HPO~4~, 0.01 M NaH~2~PO~4~, 0.025 M KCl, 0.4 M NaCl, 5 mM MgSO~4~, 0.1 M glucose adjusted to pH 7.45 with HCl) to a density of 4 × 10^7^ cells/mL. Aliquots (15 μL) were added to 13 mm coverslips, left at 4°C for 15 min, and fixed in 1 mL 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min followed by three 5-min washes in 2 mL PBS. Cells were permeabilized with 0.1% Triton X-100 in PBS for 10 min at room temperature. Samples were then blocked in 5% fish skin gelatin (FSG) in PBS containing 10% normal goat serum. The coverslips were incubated with immunopurified mouse anti-TbUGP (0.5 μg/mL) and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antiserum at 1:2000 dilution or rabbit anti-enolase antiserum at 1:4000 dilution in 1% FSG in PBS, 0.05% TX-100. Both anti-GAPDH and anti-enolase were kind gifts of Paul Michels (Catholic University of Louvain). Samples were then washed as above in PBS and incubated with 50 μL of Alexa 594-conjugated anti-mouse IgG and Alexa 488-conjugated anti-rabbit IgG for 1 h. Coverslips were mounted on glass slides, sealed with Hydromount containing 2.5% DABCO and left to dry in the dark for 30 min. Microscopy was performed on a Zeiss LSM 510 META confocal microscope.

Immunoprecipitation and western blotting of TbUGP {#sec19}
-------------------------------------------------

*T.* *brucei* bloodstream form cells (2 × 10^8^ cells) purified from rat infected blood were washed with trypanosome dilution buffer and hypotonically lysed in 200 μL of water containing 0.1 mM 1-chloro-3-tosylamido-7-amino-2-heptanone and 1 μg/mL leupeptin. The lysate was adjusted to final concentrations of 0.03% SDS and 1% Triton X-100, and an EDTA-free protease inhibitor tablet (Roche) was added, incubated at 4°C for 15 min and centrifuged (20,000 × *g* for 30 min). The pellet was discarded and the supernatant was incubated (2 h, 4°C) with 12 μg of affinity-purified rabbit anti-TbUGP previously coupled to 50 μL of 30 mg/mL protein G Dynabeads (Invitrogen). The beads were recovered by placing on the magnet for 2 min and washed three times with cold 20 mM Tris--HCl pH 7.2, 0.15 M NaCl, containing 0.03% SDS and 1% Triton X-100. The bound antigen was eluted with 50 mM sodium citrate pH 2.8 and immediately neutralized with 1.2 M Tris--HCl pH 8.8. The elution was boiled in SDS-sample buffer containing 0.1 M DTT, loaded onto 4--12% gradient NuPage gel (Invitrogen) for SDS--PAGE, and western blotted onto nitrocellulose. Briefly, the membrane was blocked with 5% (w/v) BSA, 0.05% (w/v) Tween-20 (Sigma), 0.15 M NaCl in 50 mM Tris--HCl pH 7.4, and subsequently probed with 5 μg/mL affinity-purified mouse anti-TbUGP as the primary antibody, washed and then incubated with 1:10,000 horse radish peroxidase-conjugated anti-mouse IgG (Jackson Immunoresearch, Stratech, Newmarket Suffolk, UK). After washing, the membrane was developed by chemiluminescent detection (ECL-plus, GE Healthcare).

Crystallization and data collection {#sec20}
-----------------------------------

Crystals of TbUGP were obtained from a hanging drop vaporization method consisting of 17 mg/mL protein mixed one to one with a crystallization buffer of 22% PEG 3350, 0.1 M ammonium sulfate, and 0.1 M Bis--Tris pH 5.5. Crystals were flash-cooled in crystallization buffer supplemented with 18% glycerol.

X-ray diffraction data were collected on a home source Rigaku FRE with wavelength 1.5418 Å. An initial native dataset was collected using the Rigaku software then indexed and scaled using the HKL2000 package ([@ref28]). A molecular replacement solution was found using the program BALBES ([@ref21]), which found a solution using a model from the UPG-bound form of UGP from *L.* *major* (PDB accession no. 2OEG-A). This initial dataset was partially twinned and subsequent refinement statistics were poor. Additional crystals were screened and a second dataset was collected on a less pathogenic crystal. The BALBES model was used again and refinement statistics with this dataset were much improved. The final model was built by iterative rounds of manual model building in Coot ([@ref9]) followed by refinement in the ccp4 program refmac5.2 ([@ref4]). The final model has overall good geometry, with 98% of all residues favored Ramachandran regions and no outliers. Coordinates and structure factors have been deposited to the RCSB protein databank (PDB accession no. 3GUE). Final statistics are shown in [Table I](#tab1){ref-type="table"}. Ligand interactions, close contacts, and oligomerization state within the crystal were analyzed using the program PISA ([@ref17]) and crystal figures created with the Pymol package ([@ref7]).
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Abbreviations
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BSA

:   bovine serum albumin

DTT

:   dithiothreitol

HAT

:   Human African trypanosomiasis

HEPES

:   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HPLC

:   high-performance liquid chromatography

IPTG

:   isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside

LB

:   Lysogeny broth

LmUGP

:   *Leishmania major* UDP-Glucose pyrophosphorylase

PBS

:   phosphate-buffered saline

PCR

:   polymerase chain reaction

RT

:   reverse transcription

SDS--PAGE

:   sodium dodecyl sulfate--polyacrylamide gel electrophoresis

TbUGP

:   *Trypanosoma brucei* UDP-Glucose pyrophosphorylase

UDP-Gal

:   UDP-galactose

UDP-Glc

:   UDP-glucose

UDP-GlcNAc

:   UDP-*N*-acetylglucosamine

UGGT

:   unfolded glycoprotein glucosyltransferase

UV

:   ultraviolet

VSG

:   variant surface glycoprotein
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